Osimertinib

May 07, 2020

Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea

Feb 10, 2020

Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors

Jan 19, 2020

Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC

Dec 19, 2019

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

Oct 29, 2019

Prime Therapeutics Study Finds Tagrisso® New First-line Lung Cancer Treatment Drives Ten-fold Use, $4 Million Cost Increase

Aug 05, 2019

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Mar 21, 2019

Kanazawa University Research: Origin of Resistance to Lung-cancer Drug Discovered

Sep 26, 2018

Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion

Apr 18, 2018

Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®

Apr 18, 2018

US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer